Voluntary Scheme for Branded Medicines Pricing and Access

(asked on 16th March 2023) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to publish information about the outcomes from the workshops that his Department has been running ahead of negotiations on a new Voluntary Scheme for Branded Medicines Pricing and Access.


Answered by
Will Quince Portrait
Will Quince
This question was answered on 23rd March 2023

The objective of the pre-negotiation workshops was to enable a mutual understanding of the impact of the current voluntary scheme upon the different organisations represented, and to discuss the potential objectives and priorities for a new voluntary scheme. The discussions in the workshops will feed into the upcoming negotiation of a successor to the 2019 voluntary scheme for branded medicines pricing and access. In order to facilitate a transparent and candid discussion, participants agreed that all contributions would be kept confidential to those who attended.

The following external organisations were invited to the workshops:

Industry bodies:

- Association of the British Pharmaceutical Industry

- British Generic Manufacturers Association

- Ethical Medicines Industry Group

- BioIndustry Association

Patient organisations and civil society organisations:

- Cancer52

- The Blood Cancer Alliance

- The Charity Medicines Access Coalition

- National Voices

- The Patients Association

- Alzheimer’s Research UK

- Anthony Nolan

- Cystic Fibrosis Trust

- Genetic Alliance UK

- The Association of Medical Research Charities

- Breast Cancer Now

- Myeloma UK

- Office of Health Economics

- King’s Fund

- NHS Confederation

Reticulating Splines